GlassScriptPhysician profile
Vidhya Chandramohan
NPI 1356661631
$6,058.69
in general payments reported to CMS, 2019-2025
26 companies · $613 in 2025
The $613 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,079 · 2020: $202 · 2021: $1,236 · 2022: $1,048 · 2023: $868 · 2024: $1,012 · 2025: $613.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,493.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,493.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,030.98 | 2019-2025 | |
| Abbvie INC. | $763.97 | 2021-2025 | Dalvance, Avycaz, Teflaro |
| Novartis Pharmaceuticals Corporation | $743.22 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $575.84 | 2019-2025 | Zerbaxa, Dificid, Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $574.64 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $434.77 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $262.57 | 2019-2025 | Eliquis, Camzyos |
| Alexion Pharmaceuticals, INC. | $226.36 | 2019-2025 | Ultomiris |
| Astrazeneca Pharmaceuticals LP | $212.87 | 2019-2024 | Lokelma, Farxiga |
| Gilead Sciences, INC. | $211.30 | 2021-2024 | Veklury |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.52 | 2020-2025 | Xifaxan |
| Sunovion Pharmaceuticals INC. | $151.52 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $140.82 | 2019 | |
| Boston Scientific Corporation | $105.41 | 2019-2024 | Watchman Flx |
| Paratek Pharmaceuticals, INC. | $96.09 | 2022-2023 | Nuzyra |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $80.48 | 2019-2024 | Rybelsus, Ozempic |
| Cmp Pharma, INC. | $46.19 | 2021 | |
| Sk Life Science, INC. | $38.01 | 2025 | |
| Melinta Therapeutics, LLC | $36.44 | 2021-2022 | |
| Electromed, INC. | $29.97 | 2023 | Smartvest |
| Amgen INC. | $26.81 | 2022 | |
| Lundbeck LLC | $24.32 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $24.07 | 2025 | Lifevest |
| Abbott Laboratories | $23.47 | 2024 | Mitraclip |
| Allergan, INC. | $22.32 | 2019 | |
| Philips North America LLC | $12.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vidhya Chandramohan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.